The Vytorin controversy exposes shortcomings of surrogate endpoints
The Vytorin controversy exposes shortcomings of surrogate endpoints.
Drugs are all too often approved and used due to their ability to change surrogate endpoints...blood pressure, lipids, serum glucose, etc.
The "ENHANCE" trial is a good reminder that these endpoints are not always accurate indicators of overall outcomes.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote